This double-blind phase III trial randomly assigned patients with newly diagnosed advanced ovarian cancer and a BRCA mutation in clinical response to platinum-based chemotherapy to maintenance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback